IP Library Granted Patent US 9,447,053
Granted Patent B2
US 9,447,053 · App. 13/508,198 · Granted Sep 20, 2016

Process for the preparation of calcobutrol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,053
App. No.
13/508,198
Granted
Sep 20, 2016
Kind
B2
Abstract

A process for the preparation of the calcium complex of 10-(2, 3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-4,7-triacetic acid, also known as Calcobutrol, starting from the pure gadolinium complex (Gadobutrol) is disclosed. Also disclosed is Calcobutrol with a hitherto unknown level of purity.

Claims (19)

1. A process for the preparation of a calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid comprising:

a) de-complexing a gadolinium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid with a de-complexing agent to give a solution of a free ligand and a precipitated gadolinium salt,

b) removing the precipitated gadolinium salt,

c) binding the free ligand in the solution resulting from step b) to an acidic ion exchange resin,

d) eluting the acidic ion exchange resin with an aqueous alkaline solution to give an eluate comprising the free ligand,

e) treating the eluate with a second acidic ion exchange resin to acidify the eluate comprising the free ligand, and

f) complexing the free ligand with Ca 2+ ions from a calcium ion source to give a resulting calcium complex, and crystallizing the resulting calcium complex to give a crystallized calcium complex.

2. The process according to claim 1 , wherein the de-complexing agent in step a) is an oxalate ion source or a phosphate ion source.

3. The process according to claim 2 , wherein the de-complexing agent in step a) is oxalic acid.

4. The process according to claim 1 , wherein the de-complexation reaction according to step a) is carried out in water at temperatures from 75 to 100° C.

5. The process according to claim 1 , wherein the aqueous alkaline solution of step d) is a solution of ammonia or a volatile amine, or mixtures thereof.

6. The process according to claim 5 , wherein the aqueous alkaline solution in step d) is a solution of ammonia, dimethylamine, methylamine, ethylamine, trimethylamine, iso-propylamine, or mixtures thereof.

7. The process according to claim 6 , wherein the aqueous alkaline solution in step d) is a solution of ammonia.

8. The process according to claim 1 , wherein the free ligand resulting from step e) is isolated by freeze-drying.

9. The process according to claim 1 , wherein the free ligand resulting from step e) is reacted directly with the calcium ion source without isolating the free ligand first.

10. The process according to claim 1 , wherein the calcium ion source in step f) is calcium carbonate, calcium oxide, or calcium hydroxide.

11. The process according to claim 1 , wherein a pH in step a) before adding the de-complexing agent is higher than 2.

12. The process according to claim 1 , wherein the crystallized calcium complex is the calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid having a purity of 99.0% or more.

13. The process according to claim 1 , wherein the crystallized calcium complex is the calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid having a purity of 99.4% or more.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 12, 2023
From: BAYER INTELLECTUAL PROPERTY GMBH
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 064021/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2013
From: PLATZEK, JOHANNES, DR.; TRENTMANN, WILHELM, DR.
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030076/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 029906/0035 →